L
Lewis L. Lanier
Researcher at University of California, San Francisco
Publications - 576
Citations - 93495
Lewis L. Lanier is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Interleukin 21 & Natural killer cell. The author has an hindex of 159, co-authored 554 publications receiving 86677 citations. Previous affiliations of Lewis L. Lanier include University of Rome Tor Vergata & Cancer Research Institute.
Papers
More filters
Posted ContentDOI
Heterogeneous immunological recovery trajectories revealed in post-acute COVID-19
Yu-Ru Su,Yu-Ru Su,Dan Yuan,Dan Yuan,Chen Dg,Kai Wang,Jongchan Choi,Chengzhen L. Dai,Sunga Hong,Zhang R,Zhang R,Jingyi Xie,Li S,Kelsey Scherler,Ana Jimena Pavlovitch-Bedzyk,Shen Dong,Christopher Lausted,Rachel Ng,Rachel Ng,Lee I,Shannon Fallen,Sergey A. Kornilov,Priyanka Baloni,Venkata R Duvvuri,Anderson Kg,Anderson Kg,Jessi W Li,Fan Yang,Clifford Rostomily,Pamela Troisch,Brett Smith,Jing Zhou,Sean Mackay,Murry K,Rick Edmark,Lesley Jones,Yong Zhou,Lee Rowen,Rachel Liu,Chour W,William R. Berrington,Julie A. Wallick,Heather A. Algren,Terri Wrin,Christos J. Petropoulos,Wei Wei,Nathan D. Price,Naeha Subramanian,Naeha Subramanian,Jennifer Hadlock,Andrew T. Magis,Antoni Ribas,Lewis L. Lanier,Scott D. Boyd,Jeffrey A. Bluestone,Leroy Hood,Raphael Gottardo,Raphael Gottardo,Phil Greenberg,Phil Greenberg,Mark M. Davis,Jason D Goldman,Heath +62 more
TL;DR: In this article, the authors investigated 140 COVID-19 patients from diagnosis to convalescence using clinical data, viral load assessments, and multi-omic analyses of blood plasma and circulating immune cells.
Book ChapterDOI
K562 tumor cells preferentially activate leu 11+ human large granular lymphocytes in a mixed lymphocyte response culture
Patent
Modulation of NKG2D for treating or preventing solid organ allograft rejection
Sang-Mo Kang,Lewis L. Lanier +1 more
TL;DR: In this paper, a method for disabling the expansion and function of autoreactive T cells, NK cells, and/or NKT cells by modulating NKG2D was proposed.
Journal ArticleDOI
A Single Nucleotide Polymorphism in Donor MICB Protects from NKG2D-Mediated Primary Graft Dysfunction and Death
Oscar A. Aguilar,Anita E. Qualls,Maria D. R. Gonzalez-Hinojosa,Jennifer S. Singer,Steven R. Hays,Jeffrey A. Golden,Jasleen Kukreja,Joshua M. Diamond,Judith Christie,Lewis L. Lanier,John R. Greenland,Daniel R Calabrese +11 more